# DCVC Bio

> DCVC Bio is a VC fund in San Francisco backing Biotechnology and Therapeutics. See 70 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 70
- Last investment: May 2026
- Lead investor: 59%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/dcvcbio/about/
- X (Twitter): https://twitter.com/DCVCBio
- Website: https://www.dcvc.com/companies.html#dcvc-bio

DCVC Bio is a venture capital fund that invests in early-stage life science companies driven by deep-tech approaches. Advances in genetic sequencing, artificial intelligence, and automation are converging to transform existing life sciences technologies and speed the development of new ones. The firm is looking for companies affecting deeptechnological change in synthetic biology, medicine, and agriculture.

## Contacts

5 contacts available for DCVC Bio. Shizune tracks 2 team members at DCVC Bio. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/dcvc-bio?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2M–$31M |
| Series A | $13M–$67M |
| Series B | $27M–$135M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 27 | 39% |
| Therapeutics | 13 | 19% |
| Medical | 11 | 16% |
| Pharmaceutical | 8 | 11% |
| Health Care | 7 | 10% |

35 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 28 | 40% |
| Seed | 11 | 16% |
| Series B | 10 | 14% |
| Series C | 4 | 6% |
| Funding Round | 2 | 3% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 32 | 46% |
| United Kingdom | 2 | 3% |
| Canada | 1 | 1% |
| Denmark | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andy May | Entrepreneur In Residence | 1 | https://shizune.co/investors/profile/andy-may |
| Anna Fokina | Investment Director | 0 | https://shizune.co/investors/profile/anna-fokina |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Latus Bio | Latus Bio focuses on developing innovative gene therapy candidates using precision delivery to enhance the lives of patients. Latus identified proprietary AAV capsids for clinical use. The company plans to administer low doses of its product candidates, aiming to improve clinical safety and manufacturing. | $43M | Series A | May 04, 2026 |  |
| Sidewinder Therapeutics | Sidewinder Therapeutics develops bispecific antibody-drug conjugates (ADCs) aimed at treating solid tumors. Their mission is to create life-saving therapies through precision therapeutics. | $137M | Series B | Apr 08, 2026 |  |
| AgZen | AgZen develops pesticide sprays stick to plants which reduces pollution and helps farmers save. | $10M | Series B | Mar 13, 2026 |  |
| NILO Therapeutics | NILO Therapeutics is a biotechnology and therapeutics company. | $101M | Series A | Oct 08, 2025 |  |
| Alchemab Therapeutics | Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases. They are building their transformative engine to identify novel drug targets and develop a broad pipeline of novel antibody therapeutics for hard-to-treat cancers, neurodegenerative conditions, and infectious diseases. | $32M | Series A | Sep 09, 2025 |  |
| Estes Energy | Estes Energy is a California-based startup developing advanced, U.S.-made, chemistry-agnostic battery packs for mobility and industry—supporting both NMC (for high energy density) and LFP (for cost-sensitive applications)—and targeting commercial vehicles, defense, marine, rail, and off-highway markets. | $11M | Seed | Jul 23, 2025 |  |
| Grove Biopharma | Grove Biopharma is a biotechnology company offering a materials science solution to peptide therapeutic challenges, focused on the discovery and development of a novel class of “protein-like polymers” to treat significant unmet medical needs in chronic inflammatory and neurodegenerative diseases. | $30M | Series A | Apr 23, 2025 |  |
| Solu Therapeutics | Solu Therapeutics is a precision-medicine-focused company developing therapeutics to eliminate disease-driving cells. | $41M | Series A | Apr 09, 2025 |  |
| AgZen | AgZen develops pesticide sprays stick to plants which reduces pollution and helps farmers save. | $10M | Series A | Mar 06, 2025 |  |
| Newleos Therapeutics | Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines. | $93.5M | Series A | Feb 13, 2025 |  |

10 of 70 investments shown.

## Co-investors
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 11 deals together
- [8VC](https://shizune.co/investors/profile/8vc) — VC Fund, 7 deals together
- [Northpond Ventures](https://shizune.co/investors/profile/northpond-ventures) — VC Fund, 7 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 6 deals together
- [DCVC](https://shizune.co/investors/profile/data-collective) — VC Fund, 6 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 6 deals together

## Similar investors

### Similar industry
- [SVG Ventures](https://shizune.co/investors/profile/svg-ventures) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Omnivore](https://shizune.co/investors/profile/omnivore-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)
- [Agriculture (agtech) VC Funds in United States](https://shizune.co/investors/agriculture-agtech-vc-funds-united-states)
- [Agriculture (agtech) Investors in United States](https://shizune.co/investors/agriculture-agtech-investors-united-states)
- [Agriculture (agtech) Investors in United States](https://shizune.co/investors/agriculture-agtech-investors-united-states)
- [Agriculture (agtech) VC Funds in United States](https://shizune.co/investors/agriculture-agtech-vc-funds-united-states)

## FAQ

### What does DCVC Bio invest in?

DCVC Bio invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series A and Seed stage. Most of the 70 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is DCVC Bio's check size?

DCVC Bio typically joins rounds of $2M–$31M at Seed, $13M–$67M at Series A and $27M–$135M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds DCVC Bio participates in.

### How do I contact DCVC Bio?

Public channels for DCVC Bio include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at DCVC Bio?

The team at DCVC Bio includes Andy May (Entrepreneur In Residence) and Anna Fokina (Investment Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co